Pangea is committed to the ongoing development of scientific knowledge in our field.
We are currently involved in two studies. The most recent is a Phase I & II clinical trial in Nayarit, Mexico. The other, nearing completion, is an observational study of the long-term outcomes of ibogaine treatment.
Pangea is collaborating with Dr. Raul Morales to develop a Phase I & II clinical trial for opiate detoxification with ibogaine at the University of Guadalajara in Jalisco, Mexico.
The study will enroll 12 individuals to investigate ibogaine’s safety, as well as its short term effects on opiate withdrawal and long-term (2 month) effects on craving and opiate use. The protocol has received approval from the ethics committee at the University of Guadalajara and the study will begin to enroll clients in early 2014.
Between 2009 and 2011, a number of Pangea clients were enrolled in an observational study conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), under the supervision of Dr. Thomas K Brown of the University of California in San Diego.
The study was designed to assess progress of clients for 12 months following their treatment, using various measures for addiction severity, opiate withdrawals, states of consciousness (to describe the intensity of the ibogaine experience), depression, and changes in emotional empathy.
Although it is unpublished, preliminary results were presented at both the Global Ibogaine Therapist Alliance Conference in Vancouver, October 2012, and the Psychedelic Science Conference in Oakland, April 2013 (video below courtesy of MAPS).